A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Genmab
Arcus Biosciences, Inc.
Pfizer
Pfizer
AstraZeneca
Fudan University
Tyligand Pharmaceuticals (Suzhou) Limited
M.D. Anderson Cancer Center
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hansoh BioMedical R&D Company
ImmunityBio, Inc.
ImmunityBio, Inc.
Taiho Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
Cantargia AB
Incyte Corporation
Gilead Sciences
Valerio Therapeutics
National Institutes of Health Clinical Center (CC)